<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
Trade with 70% Backtested Accuracy
Analyst Views on 01801
About the author
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
<Full-day Summary> HSI Falls by 491 Points; HSTI Declines by 114 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.
Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.
Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.
<Midday Update> HSI Falls 523 Points; HSTI Declines 127 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, SINOPHARM, KB LAMINATES Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.
Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.
Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.
HSI Drops Over 500 Points; Meituan, Chinese Insurers and Pharmacies Underperform; Standard Chartered Remains Strong; Knowledge Atlas and MiniMax Recover
Market Overview: The Hong Kong bourse opened lower, with the Hang Seng Index (HSI) dropping 509 points or 1.9% to 26,572, amid a turnover of HKD124.419 billion.
Pharmaceutical Sector Decline: Pharmaceutical stocks were the biggest losers, with notable declines in HANSOH PHARMA, SINO BIOPHARM, and CSPC PHARMA, all experiencing significant short selling.
Insurance Sector Struggles: Chinese insurers faced pressure, with major companies like CHINA LIFE and PING AN seeing substantial losses, contributing to a broader decline in the financial sector.
AI Stocks Recovery: Three AI-related semi-IPOs rebounded after previous losses, with MINIMAX-WP, KNOWLEDGE ATLAS, and HAIZHI TECH GP all posting gains and increased trading volumes.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
<Full-day Summary> HSI Falls by 491 Points; HSTI Declines by 114 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.
Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.
Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.
<Midday Update> HSI Falls 523 Points; HSTI Declines 127 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, SINOPHARM, KB LAMINATES Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.
Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.
Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.
HSI Drops Over 500 Points; Meituan, Chinese Insurers and Pharmacies Underperform; Standard Chartered Remains Strong; Knowledge Atlas and MiniMax Recover
Market Overview: The Hong Kong bourse opened lower, with the Hang Seng Index (HSI) dropping 509 points or 1.9% to 26,572, amid a turnover of HKD124.419 billion.
Pharmaceutical Sector Decline: Pharmaceutical stocks were the biggest losers, with notable declines in HANSOH PHARMA, SINO BIOPHARM, and CSPC PHARMA, all experiencing significant short selling.
Insurance Sector Struggles: Chinese insurers faced pressure, with major companies like CHINA LIFE and PING AN seeing substantial losses, contributing to a broader decline in the financial sector.
AI Stocks Recovery: Three AI-related semi-IPOs rebounded after previous losses, with MINIMAX-WP, KNOWLEDGE ATLAS, and HAIZHI TECH GP all posting gains and increased trading volumes.
